Improved Investigator Global Assessment,Allergic Contact Dermatitis-11,Dermatology Life Quality Index,and Global Quality of Life and Severity Scores after Patch Testing in Dermatitis Patients
Restricted accessResearch articleFirst published online 2026
Improved Investigator Global Assessment,Allergic Contact Dermatitis-11,Dermatology Life Quality Index,and Global Quality of Life and Severity Scores after Patch Testing in Dermatitis Patients
Abstract:Background: Contact dermatitis is a common chronic skin condition affecting quality of life (QoL). Patch testing is a key diagnostic process used in identifying allergens responsible for allergic contact dermatitis (ACD).
Objective: To investigate the impact of patch testing on QoL outcomes.
Methods: This IRB-approved registry included demographics, clinical findings, investigator global assessments (IGAs), and patch test results. QoL questionnaires (ACD-11, global severity and QoL assessments, Dermatology Life Quality Index [DLQI]) prior to and 2–6 months following patch testing were analyzed with Stata® software.
Results: From 2018 to 2025, 1246 patients underwent patch testing and received pre-patch questionnaires; 548 patients had additional post-patch test assessments. Post-patch testing, IGA, global assessments of patients’ self-reported QoL and skin severity, DLQI, aggregate and domain-specific ACD-11 assessments significantly improved (P < 0.0001). Median time to assessment was 94 days (interquartile range 77, 113). Patch patients, regardless of sex, race, ethnicity, duration of symptoms, atopic dermatitis history, total relevant allergens, number of allergens recalled, or body locations of involvement, demonstrated significant improvements in QoL (P < 0.0001). Improved IGA was associated with ACD diagnosis and younger age. 61.4% of patients correctly recalled all their culprit allergens.
Conclusion: Patch testing provided benefit to patients in multiple physician and patient-reported outcome measures. Patients had a higher rate of allergen recollection than previously reported.
HaraldstadK, WahlA, AndenæsR, et al.; LIVSFORSK network. A systematic review of quality of life research in medicine and health sciences. Qual Life Res. 2019; 28(10):2641–2650; doi: 10.1007/s11136-019-02214-9
3.
SteuerMS, BottoNC. Patient reported improvement after patch testing and allergen avoidance counseling: A retrospective analysis. Dermatol Ther (Heidelb). 2018; 8(3):435–440; doi: 10.1007/s13555-018-0250-5
4.
SimpsonEL, Bruin-WellerM, FlohrC, et al.When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the international eczema council. J Am Acad Dermatol. 2017; 77(4):623–633; doi: 10.1016/j.jaad.2017.06.042
5.
BraunbergerT, LynnD, ReimerC, et al.Disease severity and quality of life measurements in contact dermatitis: A systematic review 2005-2015. Dermatitis. 2016; 27(6):362–371; doi: 10.1097/der.0000000000000235
6.
RamirezF, ChrenMM, BottoN. A review of the impact of patch testing on quality of life in allergic contact dermatitis. J Am Acad Dermatol. 2017; 76(5):1000–1004; doi: 10.1016/j.jaad.2016.12.011
7.
SwietlikJ, ReederM. Current quality-of-life tools available for use in contact dermatitis. Dermatitis. 2016; 27(4):176–185; doi: 10.1097/der.0000000000000192
8.
RaffiJ, AllenIE, BottoN. Validating responsiveness of a quality-of-life instrument for allergic contact dermatitis. Dermatitis. 2020; 31(3):209–214; doi: 10.1097/DER.0000000000000542
9.
JohansenJD, Aalto-KorteK, AgnerT, et al.European society of contact dermatitis guideline for diagnostic patch testing - Recommendations on best practice. Contact Dermatitis. 2015; 73(4):195–221; doi: 10.1111/cod.12432
10.
HouleMC, DeKovenJG, AtwaterAR, et al.North American contact dermatitis group patch test results: 2021-2022. Dermatitis. 2025; 36(5):464–476; doi: 10.1089/derm.2024.0474
11.
PollardB, CollisRW, StahlD, et al.Changes in product use and quality of life after patch testing in children with allergic contact dermatitis. Dermatitis. 2022; 33(5):337–340; doi: 10.1097/der.0000000000000796
12.
BoonchaiW, CharoenpipatsinN, WinayanuwattikunW, et al.Assessment of the quality of life (QoL) of patients with dermatitis and the impact of patch testing on QoL: A study of 519 patients diagnosed with dermatitis. Contact Dermatitis. 2020; 83(3):182–188; doi: 10.1111/cod.13535
13.
KorkmazP, BoyvatA. Effect of patch testing on the course of allergic contact dermatitis and prognostic factors that influence outcomes. Dermatitis. 2019; 30(2):135–141; doi: 10.1097/der.0000000000000452
14.
WooPN, HayIC, OrmerodAD. An audit of the value of patch testing and its effect on quality of life. Contact Dermatitis. 2003; 48(5):244–247; doi: 10.1034/j.1600-0536.2003.00113.x
15.
RajagopalanR, AndersonR. Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat. 1997; 8(4):215–221.
16.
ThomsonKF, WilkinsonSM, SommerS, et al.Eczema: Quality of life by body site and the effect of patch testing. Br J Dermatol. 2002; 146(4):627–630; doi: 10.1046/j.1365-2133.2002.04692.x
17.
JamilWN, LindbergM. Effects of time and recall of patch test results on quality of life (QoL) after testing. Cross-sectional study analyzing QoL in hand eczema patients 1, 5 and 10 years after patch testing. Contact Dermatitis. 2017; 77(2):88–94; doi: 10.1111/cod.12734
18.
ScalfLA, GenebrieraJ, DavisMD, et al.Patients’ perceptions of the usefulness and outcome of patch testing. J Am Acad Dermatol. 2007; 56(6):928–932; doi: 10.1016/j.jaad.2006.11.034
19.
ZugKA, AaronDM, MackenzieT. Baseline quality of life as measured by Skindex-16 + 5 in patients presenting to a referral center for patch testing. Dermatitis. 2009; 20(1):21–28.
